ARTL ▼ -9.8% - Artelo Biosciences, Inc. $ARTL - Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity Artelo Biosciences fell 9.8% today despite announcing positive nonclinical data showing its ART27.13 compound achieved weight loss comparable to semaglutide alone and doubled weight loss when combined with semaglutide in an obesity model. The decline suggests investors may have focused on the nonclinical nature of the results or concerns about the company's path to clinical development and commercialization. 16-SEP-2026 07:30 AM ET